News

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Yahoo·09:30

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight

Recently published Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Yahoo·10:31

Denali Therapeutics Q2 2026 Earnings Call Transcript

On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call

Benzinga·03:55DNLI▲+3.0%

Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?

Denali Therapeutics has delivered a mixed share price journey, with sharp gains over the past year sitting against a much weaker longer track record. That kind of profile puts the spotlight firmly on whether the current stock price is aligned with the cash flows that the business can realistically produce. Over 5 years, Denali Therapeutics shares have fallen 57.3%, which makes the current valuation question largely about whether the market is now paying the right price for a business that...

Yahoo·23:22DNLI▲+3.0%

Is Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?

Denali Therapeutics (DNLI) has pulled back sharply, with the share price down about 15% over the past month and 27% in the past 3 months. This decline has drawn fresh attention to its valuation. Short term momentum for Denali Therapeutics has clearly cooled, with the 7 day share price return down 9.1% and the 3 month share price return down 27.3%, even though the year to date share price return is still up 14.8% and the 1 year total shareholder return is 15.5%. This suggests that recent...

Yahoo

Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Denali Therapeutics Inc. (DNLI) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:05 PM EDTCompany ParticipantsRyan Watts -...

SeekingAlpha·15:41DNLI▲+3.0%

B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.

Benzinga·09:47DNLI▲+3.0%

Denali Therapeutics: Bullish On Avlayah And Their Prospects

Denali Therapeutics' main improvement lies with AVLAYAH, moving it from a platform story into a commercial-stage biotech. See why DNLI stock is a buy.

SeekingAlpha·04:01DNLI▲+3.0%

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'

SeekingAlpha·07:45

Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One

Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy.

SeekingAlpha·08:13DNLI▲+3.0%

Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout

Denali Therapeutics (DNLI): perfect technical & setup scores. Uptrend with tight consolidation. Breakout above $25.84, stop below $23.01.

ChartMill·05:41DNLI▲+3.0%

UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.

Benzinga·15:37DNLI▲+3.0%

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsLaura HansenRyan Watts - Co-Founder, President, CEO...

SeekingAlpha·23:44DNLI▲+3.0%

Denali Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

2026-08-07. The following slide deck was published by Denali Therapeutics Inc.

SeekingAlpha·23:25DNLI▲+3.0%

Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates

Denali Therapeutics (DNLI) stock fell 12% after Q2 revenue miss. AVLAYAH sales low, but Q3 guidance of $10-12M signals acceleration.

ChartMill·16:52DNLI▲+3.0%

Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of $(0.72) per share

Benzinga·12:04DNLI▲+3.0%